首页 | 本学科首页   官方微博 | 高级检索  
     

体外膜肺氧合患者抗感染治疗的药学监护
引用本文:陈玥,黄絮,郭冬杰. 体外膜肺氧合患者抗感染治疗的药学监护[J]. 现代药物与临床, 2020, 43(6): 1142-1146
作者姓名:陈玥  黄絮  郭冬杰
作者单位:中国人民解放军总医院 药学部临床药学中心, 北京 100853;中日友好医院 呼吸与危重症医学部, 北京 100029;中日友好医院 药学部, 北京 100029
摘    要:目的 分析体外膜肺氧合(ECMO)时抗感染治疗药物监护的重点和难点。方法 回顾性分析28例使用体外膜肺氧合治疗的危重症患者,统计患者的临床基本情况、病原学检出、抗感染药物使用和治疗药物监测情况。结果 28例患者中男性20例,女性8例,平均年龄为44.7岁,平均ECMO持续时间20.3 d,使用ECMO前即有肝功能不全者16例、肾功能不全5例、心衰7例、低蛋白血症18例,12例合并使用持续肾脏替代治疗(CRRT),平均APACHEII评分为19.1分,SOFA评分为7.6分。ECMO撤离后最终治疗成功、存活患者7例,死亡、自动出院或放弃治疗21例。共培养出病原体55例,多数为多重耐药革兰阴性杆菌、碳青霉烯类药物耐药,治疗药物监测为万古霉素19例、碳青霉烯类11例、伏立康唑4例,血药浓度监测各品种均有超过半数未在治疗范围内。结论 ECMO影响危重患者的血药浓度,应加强对该类患者的抗感染治疗药学监护。

关 键 词:体外膜肺氧合  危重症  抗感染药物  药学监护
收稿时间:2019-09-02

Pharmaceutical care of anti-infective therapy in patients with ECMO
CHEN Yue,HUANG Xu,GUO Dongjie. Pharmaceutical care of anti-infective therapy in patients with ECMO[J]. Drugs & Clinic, 2020, 43(6): 1142-1146
Authors:CHEN Yue  HUANG Xu  GUO Dongjie
Affiliation:Clinical Pharmacist Center, People''s Liberation Army General Hospital, 100853 Beijing, China;Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, 100029 Beijing, China; Department of Pharmacy, China-Japan Friendship Hospital, 100029 Beijing, China
Abstract:Objective The emphases and difficulties of anti-infective drug monitoring in extracorporeal membrane oxygenation (ECMO) were analyzed. Methods A retrospective analysis of 28 critically ill patients treated with ECMO was performed. The clinical characteristics, pathogen detection, anti-infective agent''s application, and therapeutic drug monitoring were statistically analyzed. Results Of the 28 patients, 20 were male and 8 were female, with an average age of 44.7 years. The mean ECMO duration was 20.3 d. There were 16 patients with hepatic insufficiency, 5 patients with renal insufficiency, and 7 patients with heart failure, 18 cases of hypoproteinemia before ECMO. And there were 12 cases combined with CRRT; the average APACHE II score was 19.1 and SOFA score was 7.6. The overall outcomes were 7 patients survived, and 21 patients died or discharged automatically or abandoning therapy. A total of 55 pathogens were collected, most of which were multi-drug resistant Gram-negative bacilli and carbapenem-resistant. The therapeutic drugs application were vancomycin 19, carbapenems 11, voriconazole 4, etc. More than half of the TDM were not in the treatment range. Conclusion ECMO affects the blood concentration of anti-infective agents in critically ill patients and pharmaceutical care need to be strengthened.
Keywords:ECMO  critical care  anti-infective agents  pharmaceutical care
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号